Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial.

Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, Morriss R, Brown S, Guo B, Dourish CT, Ruhé HG, Lever AG, Veltman DJ, van Schaik A, Deckert J, Reif A, Stäblein M, Menke A, Gorwood P, Voegeli G, Pérez V, Browning M.

Trials. 2017 Nov 23;18(1):558. doi: 10.1186/s13063-017-2247-2.

2.

MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action.

Oved K, Farberov L, Gilam A, Israel I, Haguel D, Gurwitz D, Shomron N.

Front Mol Neurosci. 2017 Nov 2;10:355. doi: 10.3389/fnmol.2017.00355. eCollection 2017.

3.

Chronic high dose of captopril induces depressive-like behaviors in mice: possible mechanism of regulatory T cell in depression.

Park HS, Han A, Yeo HL, Park MJ, You MJ, Choi HJ, Hong CW, Lee SH, Kim SH, Kim B, Kwon MS.

Oncotarget. 2017 Aug 3;8(42):72528-72543. doi: 10.18632/oncotarget.19879. eCollection 2017 Sep 22.

4.

Relationship of Mean Platelet Volume To MDD: A Retrospective Study.

Cai L, Xu L, Wei L, Chen W.

Shanghai Arch Psychiatry. 2017 Feb 25;29(1):21-29. doi: 10.11919/j.issn.1002-0829.216082.

5.

A wavelet-based technique to predict treatment outcome for Major Depressive Disorder.

Mumtaz W, Xia L, Mohd Yasin MA, Azhar Ali SS, Malik AS.

PLoS One. 2017 Feb 2;12(2):e0171409. doi: 10.1371/journal.pone.0171409. eCollection 2017.

6.

Evaluation of the risk factors of depressive disorders comorbid with obstructive sleep apnea.

Cai L, Xu L, Wei L, Sun Y, Chen W.

Neuropsychiatr Dis Treat. 2017 Jan 16;13:155-159. doi: 10.2147/NDT.S122615. eCollection 2017.

7.

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.

Solem CT, Shelbaya A, Wan Y, Deshpande CG, Alvir J, Pappadopulos E.

Neuropsychiatr Dis Treat. 2016 Oct 25;12:2755-2764. eCollection 2016.

8.

Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans.

Silberberg Y, Kupiec M, Sharan R.

Sci Rep. 2016 Mar 30;6:23703. doi: 10.1038/srep23703.

9.
10.

Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Tundo A, de Filippis R, Proietti L.

World J Psychiatry. 2015 Sep 22;5(3):330-41. doi: 10.5498/wjp.v5.i3.330.

11.

Pharmacological approaches to the challenge of treatment-resistant depression.

Ionescu DF, Rosenbaum JF, Alpert JE.

Dialogues Clin Neurosci. 2015 Jun;17(2):111-26. Review.

12.
13.

The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile.

Yu LF, Brek Eaton J, Zhang HK, Sabath E, Hanania T, Li GN, van Breemen RB, Whiteaker P, Liu Q, Wu J, Chang YC, Lukas RJ, Brunner D, Kozikowski AP.

Pharmacol Res Perspect. 2014 Apr;2(2):e00026. doi: 10.1002/prp2.26. Epub 2014 Mar 12.

14.

Antidepressant-like effects of a novel 5-HT3 receptor antagonist 6z in acute and chronic murine models of depression.

Gupta D, Radhakrishnan M, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P.

Acta Pharmacol Sin. 2014 Dec;35(12):1493-503. doi: 10.1038/aps.2014.89. Epub 2014 Nov 24.

15.

Modeling the dynamics of disease states in depression.

Demic S, Cheng S.

PLoS One. 2014 Oct 17;9(10):e110358. doi: 10.1371/journal.pone.0110358. eCollection 2014.

16.

Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine.

Shah A, Carreno FR, Frazer A.

Clin Psychopharmacol Neurosci. 2014 Aug;12(2):83-93. doi: 10.9758/cpn.2014.12.2.83. Epub 2014 Aug 12. Review.

17.

Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.

Yu LF, Zhang HK, Caldarone BJ, Eaton JB, Lukas RJ, Kozikowski AP.

J Med Chem. 2014 Oct 23;57(20):8204-23. doi: 10.1021/jm401937a. Epub 2014 Jul 2. Review.

18.

Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.

Won E, Park SC, Han KM, Sung SH, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, Lee KJ, Han C, Ham BJ, Choi J, Hwang TY, Oh KS, Hahn SW, Park YC, Lee MS; Clinical Research Center for Depression.

J Korean Med Sci. 2014 Apr;29(4):468-84. doi: 10.3346/jkms.2014.29.4.468. Epub 2014 Apr 1.

19.

Antidepressants differentially related to 1,25-(OH)₂ vitamin D₃ and 25-(OH) vitamin D₃ in late-life depression.

Oude Voshaar RC, Derks WJ, Comijs HC, Schoevers RA, de Borst MH, Marijnissen RM.

Transl Psychiatry. 2014 Apr 15;4:e383. doi: 10.1038/tp.2014.14.

20.

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs.

Yoshimura R, Kishi T, Hori H, Katsuki A, Sugita-Ikenouchi A, Umene-Nakano W, Atake K, Iwata N, Nakamura J.

Psychiatry Investig. 2014 Jan;11(1):84-8. doi: 10.4306/pi.2014.11.1.84. Epub 2014 Jan 21.

Supplemental Content

Support Center